Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350565 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL29398238 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL29350888 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL288272 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL43168 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| Bromide SCHEMBL8763315 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| Hydrochloric Acid SCHEMBL7272493 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| Hydrochloric Acid SCHEMBL1202518 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| Hydrochloric Acid SCHEMBL32677098 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL28412655 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111254180-B | Method for preparing (S) -1,2,3, 4-tetrahydroisoquinoline-3-formic acid by enzymatic resolution | 浙江大学 | 2023-04-28 | — | — | CN | claimed |
| CN-111254170-B | Method for preparing (S) -1,2,3, 4-tetrahydroisoquinoline-3-formic acid by multienzyme coupling | 浙江大学 | 2023-04-28 | — | — | CN | claimed |
| CN-111254170-A | Method for preparing (S) -1,2,3, 4-tetrahydroisoquinoline-3-formic acid by multi-enzyme coupling | 浙江大学 | 2020-06-09 | — | — | CN | claimed |
| CN-105007928-A | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG | 2015-10-28 | — | — | CN | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| EP-0902781-B1 | PREPARATION OF (S)-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID T-BUTYLAMIDE | PCBU SERVICES INC (US) | 2003-12-17 | — | — | EP | claimed |
| US-20020072604-A1 | Melanocortin receptor ligands | CARPINO PHILIP A (US) | 2002-06-13 | — | — | US | claimed |
| EP-0902781-A4 | PREPARATION OF (S)-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID T-BUTYLAMIDE | NSC TECHNOLOGIES LLC (US) | 2000-07-19 | — | — | EP | claimed |
| EP-0902781-A1 | PREPARATION OF (S)-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID T-BUTYLAMIDE | Monsanto Company (US) | 1999-03-24 | — | — | EP | claimed |
| WO-1997030976-A1 | PREPARATION OF (S)-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID T-BUTYLAMIDE | MONSANTO COMPANY (US) | 1997-08-28 | — | — | WO | claimed |
| US-5587481-A | Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide | THE MONSANTO COMPANY (US) | 1996-12-24 | — | — | US | claimed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| EP-0845464-A2 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds as intermediates for camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-03 | — | — | EP | disclosed |
| CN-1165817-A | Novel metalloprotease inhibitors, process for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 1997-11-26 | — | — | CN | disclosed |
| WO-1997017050-A3 | AN IMPROVED METHOD FOR PREPARATION OF SUBSTITUTED TETRAHYDROISOQUINOLINES | MONSANTO CO (US) | 1997-06-05 | — | — | WO | disclosed |
| WO-1997017050-A2 | AN IMPROVED METHOD FOR PREPARATION OF SUBSTITUTED TETRAHYDROISOQUINOLINES | MONSANTO COMPANY (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017050-A2 | AN IMPROVED METHOD FOR PREPARATION OF SUBSTITUTED TETRAHYDROISOQUINOLINES | MONSANTO COMPANY (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072604-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC3R | GAA 3810/4885MAPT 3509/4885MEN1 770/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | GAA 818/4885MAPT 3707/4885MEN1 4811/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | GAA 2925/4885MAPT 4854/4885MEN1 4697/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | GAA 1505/4885MAPT 4114/4885MEN1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.